In recent years, interest has arisen in studying the transcription factor Nrf2 as a potential therapeutic target for the treatment of liver diseases, including epigenetic modifications that favor the activity of this endogenous antioxidant system. This evidence concerns the gene NFE2L2 and liver disorder.